На главную
Результаты поиска “Monitoring for lung cancer”
Monitoring for Recurrence in Lung Cancer
 
03:10
Philippa Cheetham, MD; Leora Horn, MD, MSc; and Kim L. Sandler, MD, consider challenges in monitoring patients for disease recurrence and comment on how advances in the field will help experts better manage lung cancer in the near future. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Просмотров: 97 curetoday
EGFR liquid biopsies: a step forward in lung cancer monitoring
 
01:46
A liquid biopsy is a simple, non-invasive alternative to surgical biopsies that enables doctors to use a simple blood sample to discover a range of information about a tumour. Traces of the cancer’s DNA in the blood can give clues about which treatments are most likely to work for a specific patient. The test can detect epidermal growth factor receptor (EGFR) gene mutations, which occur in 10-35% of patients with non-small cell lung cancer (NSCLC). To learn more about the role of liquid biopsies in monitoring lung cancer, detecting disease progression and identifying patients likely to respond to tyrosine kinase therapy, visit http://www.roche.com/liquid-biopsy. Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Просмотров: 1797 Roche
Monitoring the Emergence of T790M in EGFR-Mutated Lung Cancer
 
02:05
Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses a study monitoring the emergence of T790M in EGFR-mutated non-small cell lung cancer (NSCLC).
Просмотров: 133 Targeted Oncology
Dr. Husain on the Future of Monitoring T790M in Lung Cancer
 
01:00
Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).
Просмотров: 254 OncLiveTV
Dr. Husain on Monitoring the Emergence of T790M in Lung Cancer
 
01:41
Hatim Husain, MD, assistant professor of hematology-oncology at The University of California San Diego Moores Cancer Center, discusses his study on monitoring the emergence of EGFR T790M ctDNA in urine from EGFR mutated NSCLC.
Просмотров: 114 OncLiveTV
Catching and treating lung cancer early with electromagnetic navigation bronchoscopy
 
02:25
Electromagnetic navigation bronchoscopy (ENB) is helping doctors detect and treat lung cancer in its initial stages. Onalee is now cancer free after four years of monitoring the nodule on her lung that ended up being stage 1 lung cancer. Early intervention makes a big difference in saving lives. According to the American Cancer Society, about 160,000 Americans die of lung cancer every year, making up more than 1/4 of all cancer-related deaths.
Просмотров: 319 Ascension Borgess Hospital
The role of the blood-brain barrier in lung cancer treatment
 
03:05
Some types of cancer, such as anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), frequently spread into the brain and central nervous system. A key challenge in treating these brain metastases is the blood-brain barrier, which guards the brain against the entry of certain molecules. Learn why crossing the blood-brain barrier is important in overcoming certain cancers. To learn how to overcome the blood-brain barrier, visit http://www.roche.com/brain_shuttle. For more information on lung cancer, visit http://www.roche.com/lung-cancer. Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Просмотров: 12448 Roche
Understanding mutations in lung cancer
 
04:23
Просмотров: 7913 LUNGevityFoundation
Andy’s lung cancer journey
 
03:25
Andy was diagnosed with ALK-positive lung cancer in August 2017, having experienced symptoms of a tumour that had spread to his brain. Thanks to dramatic improvements in the diagnosis and treatment of lung cancer, Andy has been able to go back to work and continue planning for the future. Here he tells his story. Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Просмотров: 414 Roche
Owlstone LuCID - A Breathalyzer for Lung Cancer
 
01:59
The LuCID (Lung Cancer Indicator Detection) project is researching the early, non-invasive diagnosis of lung cancer by measuring volatile organic compounds in patients' breath. The goal of the project is to save 10,000 lives and save the NHS £254m by 2020, through an increase in the early stage detection rate for lung cancer.
Просмотров: 1061 Billy Boyle
Lung Cancer Living Room™ - Making Sense of Immunotherapy for Lung Cancer - 09/18/18
 
02:21:16
Topic: Making Sense of Immunotherapy for Lung Cancer " A Patients Guidebook" Speaker: Dr. David Gandara - UC Davis Cancer Center
Просмотров: 230 Addario Lung Cancer Foundation
Tumor Testing: Understanding Your Unique Lung Cancer
 
02:30
Listen to Dr. Mark Pool and lung cancer survivors, Lisa and Jennifer, talk about the importance of lung cancer tumor testing. Generously supported by AstraZeneca, Boehringer Ingelheim and Novartis.
Просмотров: 7763 LUNG FORCE
CNS Metastasis in ALK positive lung cancer
 
02:34
Frank Griesinger, MD, PhD from the Pius-Hospital Oldenburg, Oldenburg, Germany discusses the question of central nervous system (CNS) metastasis in patients with ALK positive tumors. CNS metastasis is a big issue in when treating ALK-positive tumors. Approximately 30% of patients show CNS metastasis even before they are treated with an ALK inhibitors, but after first treatment with an ALK inhibitor, 60-70% show CNS metastasis. Dr Griesinger explains that having targeted drugs that effectively target the CNS metastases would allow to delay whole-brain irradiation, thus delaying the associated cognitive impairment experienced by patients. Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
Просмотров: 195 VJOncology
Owlstone Medical LuCID Lung Cancer Breathalyzer
 
02:19
Просмотров: 3525 Billy Boyle
Non-Small Cell Lung Cancer Clinical Trial
 
02:55
Nasser Hanna, MD, discusses a phase II trial of concurrent chemoradiation with consolidation Pembrolizumab for the treatment of inoperable or unresectable stage III non-small cell lung cancer (NSCLC). Hoosier Cancer Research Network: LUN14-179 http://www.hoosiercancer.org/clinical-trials
Просмотров: 226 Hoosier Cancer Research Network
Targeted therapies for lung cancer: challenges in side effect management.
 
02:40
Rachel Thomas, lung cancer clinical nurse specialist at Guy's and St Thomas' NHS Foundation Trust, London, UK talks about running a clinic for patients on oral targeted therapies for lung cancer. She explains that monitoring and managing the side effects of treatment are the main challenges, as patients are not always able to recognize and accurately record side effects.
Просмотров: 21 VJOncology
Blood tests for identifying and monitoring ALK-positive non-small cell lung cancer
 
01:02
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the detection of anaplastic lymphoma kinase gene (ALK) rearrangements and fusions in patients with non-small cell lung cancer.
Просмотров: 82 VJOncology
Overview of the world of EGFR mutant lung cancers
 
03:38
Barbara Melosky, MD, FRCPC, of the University of British Columbia, Vancouver, BC discusses how the world of epidermal growth factor receptor (EGFR) mutating lung cancers has changed in terms of management, understanding, and the choices which are available. Research is investigating which patients might benefit from certain medications, as choice is expanding with each generation of drugs. There are first-generation EGFR tyrosine kinase inhibitors (TKIs); gefitinib, and erlotinib, second generation EGFR TKIs; afatinib, dacomitinib, and third generation; osimertinib. Dr Melosky is most excited about AURA3 data for osimertinib (NCT02151981). The choices today in the first-line setting for patients depend on the type of EGFR mutation. Mutation types are broken up into 3 categories; exon 19 deletion, exon 21 L858R, and an uncommon mutation. Following determining mutation type, it is important to communicate and educate the patient on, for example, survival rates. LUX-Lung 3 and 6 trial data has shown that exon 19 deletion has an overall significant survival benefit (NCT00949650 and NCT01121393) and in young patients, it is important to communicate this. From the LUX-Lung 7 Phase II trial, there was an observed improvement in progression-free survival (PFS), time to treatment failure, and interestingly, a 30% improvement in response rate by RECIST criteria for the exon 21 L858R mutation (NCT01466660). Another lesson to learn is that for patients with exon 21 L858R mutation needing a robust response, the best choice of drug is afatinib. For patients who are elderly, live far away from a cancer center, or where communication is poor, gefitinib may be a good choice according to Dr Melosky. AURA3 data might show that patients who develop an exon 20 T790M mutation are suited to osimertinib. From LUX-Lung 7 data, in patients either on gefitinib or afatinib that went on to osimertinib, survival is approaching 4-5 years. In conclusion, the future is looking bright for EGFR mutation patients, and hopefully this is becoming a chronic disease. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
Просмотров: 747 VJOncology
Immunotherapy in second-line treatment of non-small cell lung cancer
 
01:30
Benjamin Besse, MD, PhD, Institut Gustave Roussy, Paris, France, provides an overview of the status of immunotherapies for second-line treatment of non-small cell lung cancer. There is a lot of debate in the oncology community as to whether PD-L1 testing should be an essential prerequisite for patient selection. Prof Besse highlights recent studies that showed a detrimental effect of immunotherapy relative to chemotherapy in a subset of PD-L1 negative patients, and that this should be taken into consideration despite the lack of clinical markers and biomarkers to identify these patients. Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
Просмотров: 88 VJOncology
Saving Lives with Lung Cancer Screening
 
01:43
At Roswell Park, our High Risk Lung Cancer Screening Program is designed to detect lung cancer at its earliest, most curable stages by screening and monitoring the people most likely to develop the disease, especially smokers. Learn more at http://www.roswellpark.org/highrisklung.
Просмотров: 66 RPCICancerTalk
Lung cancer: benefits of liquid biopsy
 
02:24
Gustave Roussy presents at ASCO 2017 two studies showing the advantages of liquid biopsy (blood test) to detect genetic mutations in tumoral cells’ DNA in order to target the treatment and to monitor the disease. Prof. Benjamin Besse (Gustave Roussy, France) explanations.
Просмотров: 234 Gustave Roussy
Tumor Markers in Cancer diagnosis and Monitoring
 
09:47
A substance produced by a tumor or by the host in response to the tumor’s presence & can be detected in blood, body fluids or tissue of the host
Просмотров: 11553 Pathology Simplified
How Myriad's myPlan Addresses the Risk of Recurrence in Lung Cancer
 
02:20
Benjamin P. Levy, MD, assistant professor at the Icahn School of Medicine, medical director of the Thoracic Oncology Program, Mount Sinai Health Systems, and associate director of the Cancer Clinical Trials Office at Mount Sinai Hospital in New York, discusses how Myriad's myPlan addresses the risk of recurrence in lung cancer.
Просмотров: 95 Targeted Oncology
Lung Cancer Clinical Trials: Advances in Immunotherapy
 
29:41
NCI’s Dr. Shakun Malik, head of thoracic oncology therapeutics, and Janet Freeman-Daily, lung cancer patient activist and founding member of #LCSM, host a 30-minute Facebook Live event. The event streamed on November 17 at 8:00 pm ET on http://www.Facebook.com/cancer.gov. For more information on lung cancer, go to http://www.cancer.gov/lung
Просмотров: 737 National Cancer Institute
PHI@BOS: Remy discusses his lung cancer relapse
 
01:02
Red Sox announcer Jerry Remy shares that he has been diagnosed with lung cancer and announces that he will be getting surgery Check out http://MLB.com/video for more! About MLB.com: Former Commissioner Allan H. (Bud) Selig announced on January 19, 2000, that the 30 Major League Club owners voted unanimously to centralize all of Baseball's Internet operations into an independent technology company. Major League Baseball Advanced Media (MLBAM) was formed and charged with developing, building and managing the most comprehensive baseball experience available on the Internet. In August 2002, MLB.com streamed the first-ever live full length MLB game over the Internet when the Texas Rangers and New York Yankees faced off at Yankee Stadium. Since that time, millions of baseball fans around the world have subscribed to MLB.TV, the live video streaming product that airs every game in HD to nearly 400 different devices. MLB.com also provides an array of mobile apps for fans to choose from, including At Bat, the highest-grossing iOS sports app of all-time. MLB.com also provides fans with a stable of Club beat reporters and award-winning national columnists, the largest contingent of baseball reporters under one roof, that deliver over 100 original articles every day. MLB.com also offers extensive historical information and footage, online ticket sales, official baseball merchandise, authenticated memorabilia and collectibles and fantasy games. Major League Baseball consists of 30 teams split between the American and National Leagues. The American League consists of the following teams: Baltimore Orioles; Boston Red Sox; Chicago White Sox; Cleveland Indians; Detroit Tigers; Houston Astros; Kansas City Royals; Los Angeles Angels ; Minnesota Twins; New York Yankees; Oakland Athletics; Seattle Mariners; Tampa Bay Rays; Texas Rangers; and Toronto Blue Jays. The National League, originally founded in 1876, consists of the following teams: Arizona Diamondbacks; Atlanta Braves; Chicago Cubs; Cincinnati Reds; Colorado Rockies; Los Angeles Dodgers; Miami Marlins; Milwaukee Brewers; New York Mets; Philadelphia Phillies; Pittsburgh Pirates; San Diego Padres; San Francisco Giants; St. Louis Cardinals; and Washington Nationals. Visit MLB.com: http://mlb.mlb.com Subscribe to MLB.TV: http://mlb.tv Download MLB.com At Bat: http://mlb.mlb.com/mobile/atbat Download MLB.com Ballpark: http://mlb.mlb.com/mobile/attheballpark Download MLB.com Clubhouse: http://mlb.com/clubhouse Play Beat The Streak: http://mlb.mlb.com/bts Get MLB Tickets: http://mlb.mlb.com/tickets Get Official MLB Merchandise: http://mlb.mlb.com/shop Connect with us: YouTube: http://youtube.com/MLB Facebook: http://facebook.com/mlb Instagram: http://instagram.com/mlb Twitter: http://twitter.com/mlb Pinterest: http://pinterest.com/mlbofficial Tumblr: http://mlb.tumblr.com Google+: http://plus.google.com/+MLB
Просмотров: 120 MLB
A new prognostic test for lung cancer using blood samples instead of biopsies
 
03:52
Laboratory staff have developed and now deliver a clinical service that uses circulating tumour DNA for the detection of biomarkers in a cancer patient's blood sample. This enables the monitoring of a cancer patient in real-time to aid treatment decisions, and avoids invasive and costly surgical procedures. The technology has currently been employed in clinical practice across Wales for lung cancer, and they are also receiving requests for analysis from clinical sites across the UK. The technology may also be applied for other cancer types, for which work is now in progress. The development and validation of this technology from a research tool to a clinical diagnostic service has taken several years and research projects. These have been supported by the Wales Cancer Research Centre, the Stepping Stones Charity, Velindre Charitable Funds and AstraZeneca. Laboratory staff have worked in collaboration with clinical teams and patients across South Wales in the development and roll-out of this new clinical service.
Просмотров: 177 Wales Cancer Research Centre
Health Monitor
 
03:36
The world's first device for non-invasive detection of diabetes, stomach ulcer and lung cancer indicators https://healthmonitor.pro/
Просмотров: 1107 Health Monitor
Lung Cancer Screening Program
 
00:21
The Comprehensive Lung Program at Sunrise Hospital & Medical Center’s goal is to diagnose lung cancer in its earliest stage possible. We are committed to educating the community in Las Vegas, Clark County and surrounding communities on the importance of lung cancer screening along with monitoring any incidental findings found on patients imaging studies while a patient at our hospital.
Просмотров: 47 Sunrise Hospital & Medical Center
CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy
 
02:30
Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy. http://cancergrace.org/lung/2016/04/13/gcvl_lu_cns_disease_alk-positive_nsclc_monitoring_systemic_radiation_therapy/
Small biopsies, big deal: practical approach to lung cancer diagnosis
 
01:04:36
This is one of three lung pathology lectures I gave in July 2017 at the Colorado Society of Clinical Pathologists' annual "Stars in the Mountains" meeting in Vail, Colorado. It addresses a few key areas of diagnostic difficulty for pathologists in the diagnosis of lung cancer using small lung biopsies (core needle biopsies, transbronchial biopsies, endobronchial biopsies)
Просмотров: 1465 Sanjay Mukhopadhyay
Using liquid biopsies to hunt for tumour cells
 
03:37
Getting a biopsy of lung cancer is challenging for doctors and for the patient. Professor Caroline Dive and her lab are developing new ways to study lung cancer using just a simple sample of blood. They’re working on tests that can pick up circulating tumour cells in a patient’s blood that have broken off from the tumour. This could give doctors access to valuable information about a patient’s disease and could help monitor their response to treatment.
Просмотров: 2214 Cancer Research UK
New Drug for Lung Cancer
 
01:50
It's being hailed as a breakthrough medicine; a twice-daily pill that targets the growth of a specific type of lung cancer. The FDA fast-tracked its approval. "I think it was very exciting because it's sort of a proof that these targeted therapies for cancers can be affective," says Dr. Lowell Hart, a hematologist/oncologist on the medical staff of Lee Memorial Health System. Dr. Lowell Hart has three patients on the drug, now named Xalkori. He saw the drug make a dramatic impact. "It was very impressive to me that these were sick patients who had had their cancer progress through chemotherapy no longer working on chemo, so we would expect them to not do very well and perhaps not live very long but have had very dramatic responses to the drug," says Dr. Hart. The drug only works on the 5-10% of lung cancers which have a specific gene knows as ALK. Many people with it are non-smokers who developed 'small lung cancer'. "All three of my patients that have this mutation are women and non-smokers," says Dr. Hart. The new drug blocks protein produced by the ALK gene. It's a targeted therapy, which researchers believe is the future of controlling or curing cancer. The FDA also approved a screening test. "I am personally checking everybody and I think you know my partners are in general checking everybody and the tests are now commercially available," says Dr. Hart. Xalkori comes with a high price tag, upwards of $100,000 a year, on par with traditional chemo. Drug maker Pfizer is expected to work with insurance companies to limit out of pocket expenses, important in making the drug available to those who need it. "I've seen that very few times in my career of over 25 years. I said this drug is the real thing," says Dr. Hart. View More Health Matters video segments at leememorial.org/​healthmatters/​ Lee Memorial Health System in Fort Myers, FL is the largest network of medical care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For nearly a century, we've been providing our community with everything from primary care treatment to highly specialized care services and robotic assisted surgeries. Visit leememorial.org
Просмотров: 997 Lee Health
Margery’s Story│ Proton Therapy for Lung Cancer
 
03:31
http://www.sccaprotontherapy.com What Margery thought would be nothing was actually a large tumor on her right lung. So she decided to do something about it, approaching Dr. Ramesh Rengan, Medical Director of SCCA Proton Therapy Center in Seattle, Washington—with a warm, positive presence and a bright, infectious smile. Margery, likewise, felt comfortable around Dr. Rengan, appreciating his knowledge and confidence, and the team that he has surrounded himself with at the cancer center. After he took her through the different options for treatment, she knew with complete certainty that she wanted to proceed with proton therapy. In a room that reminded her of Star Wars and with a proton beam she called her “American Sniper,” Margery experienced her own story. And today, it continues on into the next chapters—of circuit training, Tai Chi and a generally strong life to come.
Просмотров: 58225 SCCA Proton Therapy
Lung Cancer Forum: The Clinical Perspective
 
13:59
A presentation by A/Prof Tom John, Medical Oncologist at the Lung Cancer Forum, Empowering the Patient Voice, as part of the 7th Australian Lung Cancer Conference on 5 April 2018.
Просмотров: 45 Lung Foundation Australia
Dispelling Myths Surrounding Lung Cancer
 
06:49
Dr. Leora Horn and Chris Draft remark on types of risk factors, aside from smoking, that potentially play a role in lung cancer, and remark on considerations for connecting patients to appropriate healthcare professionals when monitoring and managing the disease. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Просмотров: 19 curetoday
ALK Lung Cancer and Crizotinib Update
 
12:46
Jamey Skillings, MD, Sr. Dir. Oncology Pfizer: The development of Crizotinib and the journey of bringing new drugs to market.
Просмотров: 2352 Vital Options International
Lung Cancer Living Room - 10-17-17
 
01:59:56
Sherri Millis PhD-Senior Medical Science Liaison at Foundation Medicine Topic: Comprehensive Genomic Profiling- what it means for YOUR cancer
Просмотров: 45 Peninsula Television
Progress in the treatment of ALK-positive non-small cell lung cancer
 
00:58
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, provides an overview of the improvements in the treatment of patients with non-small cell lung cancer (NSCLC) carrying the anaplastic lymphoma kinase (ALK) gene rearrangement, including ALK-targeted therapies with improved blood–brain barrier penetrance and understanding of resistance mechanisms.
Просмотров: 131 VJOncology
Proton Therapy for Lung Cancer
 
01:19
Web: http://www.procure.com Live Chat: http://bit.ly/1brHjO7
Просмотров: 925 ProCure ProtonTherapy Center
Part 1 of 2, Isodose Based Methodology, Lung Cancer Radiosurgery Planning Example
 
05:30
Walkthrough of a lung radiosurgery case using the isodose based methodology to minimize the morbidity and mortality of treatment. Narrated by Hiram Gay, radiation oncologist, and Karen Fish, medical dosimetrist. This video is intended for instructional purposes only. Always use the most recent and validated dose volume contraints, treatment techniques and dose prescriptions in the literature. Based on the journal article: Isodose-based methodology for minimizing the morbidity and mortality of thoracic hypofractionated radiotherapy. Published in Radiotherapy & Oncology and authored by Hiram A. Gay, Claudio H. Sibata, Ron R. Allison, and Branislav Jeremic. PMID: 19058867
Просмотров: 6194 hiramag
Will Lung Cancer Treatment Affect Other Organs?
 
02:59
Dr. Hanson explains that chemotherapy treatment for lung cancer can often affect other organs, such as the blood organ, bone marrow, and nerves. Patients that undergo treatment through radiation can also expect that organs hit by the radiation could suffer damage. David S. Hanson, MD, FACP: Oftentimes patients under treatment for lung cancer are concerned about the effects their therapy may have on their body and this is entirely appropriate. Patients who receive chemotherapy for lung cancer can expect that there may damage done to other organs. The most common is the blood organ or the bone marrow and that is because the chemotherapy arrest the growth of those cells, which may cause anemia, which is a low grade blood count and can cause weakness and fatigue or low white cell counts, which can predispose a person to infection or low platelet counts, which may predispose to bleeding. For that reason, during the course of treatment, your doctor will be monitoring your blood counts and likely adjusting your chemotherapy should there be major abnormalities that develop. There are other organs that are also at risk for damage during lung cancer treatment. The most common concern are the nerves. The common chemotherapy that works very well for lung cancer can cause numbness and tingling to come in the hands and feet, that this does not occur for all patients but you and your physician will be monitoring carefully for this and probably make adjustments in your treatment should such damage occur. Many times, if that damage is detected early it can be reversed. There are other organs that are at risk for damage from chemotherapy, which include the liver and the kidneys. The doctor will obtain blood test generally to determine whether or not these organs are functioning normally and if they are not, make adjustments in your treatment. The important thing to know is that you and your doctor will be working as a team to look at the side effects of your treatment and make plans about modifying your treatment to respect those side effects that develop. Finally, there are times when patients must have radiation treatment as a part of their lung cancer treatment plan and radiation can do damage to the organs at which it is end. For that reason your radiation oncologist will make a very careful treatment plan, talk with you about what tissues might be at risk for damage and list out for you those things that you and he or she can do to manage those side effects. Commonly, there may be a skin burn that is apparent on the skin and the area that is given radiation. Proper treatment of the skin can control the symptoms from that irritation and make it far less of a difficult thing to manage than if its not attended too properly. David S. Hanson, MD practices oncology and internal medicine in Baton Rouge and Zachary, Louisiana. Dr. Hanson graduated with an MD 27 years ago.
Просмотров: 442 Best Doctors
Live @ ASCO 2016  Ask the Lung Cancer Experts
 
18:10
John Ratzenberger, Lung Cancer Advocate and Director of Strategic Relations at LUNGevity interviews Liza Villaruz, MD Hematology/Oncolgy Specialist Univeristy of Pittsburgh Medical Center and Charu Aggarwal, MD, MPH, Assistant Professor of Medicine University of Pennsylvania Health System
Просмотров: 3 Patient Empowerment Network
Optimal Specimen Collection for Biomarker Testing in Lung Cancer
 
01:18:14
Moderated by: Bob McGonnagle, Publisher, CAP TODAY Presenters: Sinchita Roy-Chowdhuri, MD, PhD, and Dara L. Aisner, MD, PhD • Listen to national thought leaders discuss the critical issue of specimen collection • Identify key issues in biomarker testing of specimens in lung cancer • Evaluate the relationship between specimen, test results, and guidelines • Understand the benefits of best practices in precision medicine and pathology For more information: http://www.captodayonline.com Originally broadcast: October 25, 2017 CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a promotional sponsorship from Genentech.
Просмотров: 242 CAP TODAY
Dr. James Cox Discusses New Phase II Lung Cancer Study at the Proton Therapy Center
 
06:37
Dr. Cox explains the outcomes of proton therapy with concurrent chemotherapy, how lung cancer patients typically tolerate treatment and what the future holds for lung cancer patients being treated with proton therapy at MD Anderson. For more information on MD Anderson's Proton Therapy Center you can visit the website at http://mdanderson.org/proton
Просмотров: 7065 MD Anderson Cancer Center
Pioneering Lung Cancer Guide to breathing exercises when in a prone position
 
06:19
This video guide has been developed by physiotherapists to make breathing feel easier. It describes exercises to be conducted when you are lying down. The exercises help you to stretch the sides of your ribcage. We offer the videos as something practical to take away from our Pioneering Lung Cancer site. The complete set of videos are featured on the free Lung+ App, which is available on iTunes and Google Play. http://www.pioneeringhealthcare.com/lung-cancer/living-with-lung-cancer/mobile-app/ More Videos from Roche on http://www.youtube.com/user/roche
Просмотров: 1676 Roche
Novel Therapies In Small Cell Lung Cancer (SCLC): Lurbinectedin
 
05:31
Lung Cancer Video Library http://cancerGRACE.org/